491 related articles for article (PubMed ID: 26889958)
21. Phospholipid Component Defines Pharmacokinetic and Pharmacodynamic Properties of Synthetic High-Density Lipoproteins.
Fawaz MV; Kim SY; Li D; Ming R; Xia Z; Olsen K; Pogozheva ID; Tesmer JJG; Schwendeman A
J Pharmacol Exp Ther; 2020 Feb; 372(2):193-204. PubMed ID: 31776208
[TBL] [Abstract][Full Text] [Related]
22. High-Density Lipoprotein Mimetics: a Therapeutic Tool for Atherosclerotic Diseases.
Ikenaga M; Higaki Y; Saku K; Uehara Y
J Atheroscler Thromb; 2016; 23(4):385-94. PubMed ID: 26830201
[TBL] [Abstract][Full Text] [Related]
23. Natural low- and high-density lipoproteins as mighty bio-nanocarriers for anticancer drug delivery.
Mahmoudian M; Salatin S; Khosroushahi AY
Cancer Chemother Pharmacol; 2018 Sep; 82(3):371-382. PubMed ID: 29915981
[TBL] [Abstract][Full Text] [Related]
24. The Composition of Reconstituted High-Density Lipoproteins (rHDL) Dictates the Degree of rHDL Cargo- and Size-Remodeling via Direct Interactions with Endogenous Lipoproteins.
Pedersbæk D; Kræmer MK; Kempen PJ; Ashley J; Braesch-Andersen S; Andresen TL; Simonsen JB
Bioconjug Chem; 2019 Oct; 30(10):2634-2646. PubMed ID: 31487985
[TBL] [Abstract][Full Text] [Related]
25. Reconstituted HDL as a therapeutic delivery device.
Fox CA; Moschetti A; Ryan RO
Biochim Biophys Acta Mol Cell Biol Lipids; 2021 Nov; 1866(11):159025. PubMed ID: 34375767
[TBL] [Abstract][Full Text] [Related]
26. Effect of Synthetic High Density Lipoproteins Modification with Polyethylene Glycol on Pharmacokinetics and Pharmacodynamics.
Li D; Fawaz MV; Morin EE; Ming R; Sviridov D; Tang J; Ackermann R; Olsen K; Remaley AT; Schwendeman A
Mol Pharm; 2018 Jan; 15(1):83-96. PubMed ID: 29141139
[TBL] [Abstract][Full Text] [Related]
27. Development of novel HDL-mimicking α-tocopherol-coated nanoparticles to encapsulate nerve growth factor and evaluation of biodistribution.
Prathipati P; Zhu J; Dong X
Eur J Pharm Biopharm; 2016 Nov; 108():126-135. PubMed ID: 27531623
[TBL] [Abstract][Full Text] [Related]
28. Composition, structure and substrate properties of reconstituted discoidal HDL with apolipoprotein A-I and cholesteryl ester.
Dergunov AD; Shabrova EV; Dobretsov GE
Spectrochim Acta A Mol Biomol Spectrosc; 2010 Mar; 75(3):1100-7. PubMed ID: 20079684
[TBL] [Abstract][Full Text] [Related]
29. Probing the Assembly of HDL Mimetic, Drug Carrying Nanoparticles Using Intrinsic Fluorescence.
Raut S; Garud A; Nagarajan B; Sabnis N; Remaley A; Fudala R; Gryczynski I; Gryczynski Z; Dzyuba SV; Borejdo J; Lacko A
J Pharmacol Exp Ther; 2020 Apr; 373(1):113-121. PubMed ID: 31941718
[TBL] [Abstract][Full Text] [Related]
30. Beginning to understand high-density lipoproteins.
Santos-Gallego CG; Badimon JJ; Rosenson RS
Endocrinol Metab Clin North Am; 2014 Dec; 43(4):913-47. PubMed ID: 25432389
[TBL] [Abstract][Full Text] [Related]
31. High-density lipoprotein apolipoprotein A-I kinetics: comparison of radioactive and stable isotope studies.
Ooi EM; Watts GF; Farvid MS; Chan DC; Allen MC; Zilko SR; Barrett PH
Eur J Clin Invest; 2006 Sep; 36(9):626-32. PubMed ID: 16919045
[TBL] [Abstract][Full Text] [Related]
32. [Advances in apolipoprotein A- I and it's anti-atherosclerosis properties].
Li M; Liu ZM
Sheng Wu Gong Cheng Xue Bao; 2003 Jul; 19(4):387-91. PubMed ID: 15969051
[TBL] [Abstract][Full Text] [Related]
33. A Simple Method to Extract Whole Apolipoproteins for the Preparation of Discoidal Recombined High Density Lipoproteins as Bionic Nanocarriers for Drug Delivery.
Zhang W; Wang J; Jia J; Chen L; Wu Z; Liu J
J Pharm Pharm Sci; 2015; 18(2):184-98. PubMed ID: 26158284
[TBL] [Abstract][Full Text] [Related]
34. ApoA-I mimetic peptides promote pre-β HDL formation in vivo causing remodeling of HDL and triglyceride accumulation at higher dose.
Carballo-Jane E; Chen Z; O'Neill E; Wang J; Burton C; Chang CH; Chen X; Eveland S; Frantz-Wattley B; Gagen K; Hubbard B; Ichetovkin M; Luell S; Meurer R; Song X; Strack A; Langella A; Cianetti S; Rech F; Capitò E; Bufali S; Veneziano M; Verdirame M; Bonelli F; Monteagudo E; Pessi A; Ingenito R; Bianchi E
Bioorg Med Chem; 2010 Dec; 18(24):8669-78. PubMed ID: 21115285
[TBL] [Abstract][Full Text] [Related]
35. Synthetic lipoprotein as nano-material vehicle in the targeted drug delivery.
Zhang X; Huang G
Drug Deliv; 2017 Dec; 24(sup1):16-21. PubMed ID: 29069931
[TBL] [Abstract][Full Text] [Related]
36. The effect of HDL mimetic peptide 4F on PON1.
Vakili L; Hama S; Kim JB; Tien D; Safarpoor S; Ly N; Vakili G; Hough G; Navab M
Adv Exp Med Biol; 2010; 660():167-72. PubMed ID: 20221879
[TBL] [Abstract][Full Text] [Related]
37. Synthetic high-density lipoprotein-like nanoparticles for cancer therapy.
Foit L; Giles FJ; Gordon LI; Thaxton CS
Expert Rev Anticancer Ther; 2015 Jan; 15(1):27-34. PubMed ID: 25487833
[TBL] [Abstract][Full Text] [Related]
38. Tanshinone IIA-loaded reconstituted high density lipoproteins: Atherosclerotic plaque targeting mechanism in a foam cell model and pharmacokinetics in rabbits.
Zhang W; Li J; Liu J; Wu Z; Xu Y; Wang J
Pharmazie; 2012 Apr; 67(4):324-30. PubMed ID: 22570939
[TBL] [Abstract][Full Text] [Related]
39. Complete high-density lipoproteins in nanoparticle corona.
Hellstrand E; Lynch I; Andersson A; Drakenberg T; Dahlbäck B; Dawson KA; Linse S; Cedervall T
FEBS J; 2009 Jun; 276(12):3372-81. PubMed ID: 19438706
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the Combined Effect of Recombinant High-Density Lipoprotein Carrier and the Encapsulated Lovastatin in RAW264.7 Macrophage Cells Based on the Median-Effect Principle.
Jiang C; Zhao Y; Yang Y; He J; Zhang W; Liu J
Mol Pharm; 2018 Mar; 15(3):1017-1027. PubMed ID: 29382194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
